ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Sunday, November 10, 2019

9:00AM-11:00AM
Abstract Number: 588
The Gut Enthesis Axis Coming into Focus with the Description of Enriched Entheseal Resident Mucosal Associated Invariant T-cells (MAITs) Capable of IL17A and TNF Production
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features
9:00AM-11:00AM
Abstract Number: 422
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes
9:00AM-11:00AM
Abstract Number: 43
The Impact of Air Pollution on Extracellular Vesicles as a Potential Pro-inflammatory Stimulus in Rheumatoid Arthritis
RA – Etiology & Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 563
The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features
9:00AM-11:00AM
Abstract Number: 156
The Impact of Spaced Education and Reciprocal Peer Teaching on Rheumatology Fellows’ Long-term Recall from Core Curriculum
Education Poster
9:00AM-11:00AM
Abstract Number: 523
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
RA – Treatments Poster I: Novel Treatments
9:00AM-11:00AM
Abstract Number: 188
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Epidemiology & Public Health Poster I: RA
9:00AM-11:00AM
Abstract Number: 374
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies
9:00AM-11:00AM
Abstract Number: 117
The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 478
The Influence of Gender on Composite Disease Activity Indices for Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis
9:00AM-11:00AM
Abstract Number: 458
The Influence of Mediterranean Diet in Rheumatoid Arthritis: A Monocenter Cross-sectional Study
RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis
9:00AM-11:00AM
Abstract Number: 779
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever
9:00AM-11:00AM
Abstract Number: 722
The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Systemic Sclerosis & Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 737
The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease
Systemic Sclerosis & Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 696
The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
SLE – Clinical Poster I: Epidemiology & Pathogenesis
  • «Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology